Pharmacists’ Role in Helping Patients Manage COPD | ASHP Midyear
Drug Topics
DECEMBER 12, 2024
Lourdes Cross, PharmD, BCACP, CDCES, discussed chronic obstructive pulmonary disease and how pharmacists are positioned to help patients exacerbations.
Sat.Dec 07, 2024 - Fri.Dec 13, 2024
469 
Gilead to test once-a-year HIV prevention shot
STAT
DECEMBER 11, 2024
Gilead said Tuesday that it will soon begin Phase 3 testing for a drug it believes could prevent HIV infection with just a single shot every year. Such a medicine, if proven effective, would be the closest thing to a vaccine the HIV field has produced in four decades of research. The company plans to begin the trial next year, with an eye toward regulatory filings in late 2027.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Will the ‘anti-woke’ movement derail DEI efforts in pharma?
PharmaVoice
DECEMBER 13, 2024
Amid the DEI backlash in corporate America, pharma leaders are quietly adjusting tactics.
Switching from Trulicity to Ozempic
The Checkup by Singlecare
DECEMBER 10, 2024
Trulicity (dulaglutide) and Ozempic (semaglutide) are both brand-name medications approved by the Food and Drug Administration (FDA) to help treat Type 2 diabetes. Because these drugs suppress appetite, some healthcare providers prescribe them off-label for weight loss. However, another medication with the same active ingredient as Ozempic has been FDA approved for weight loss and is sold under the brand name Wegovy.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Patients Before Monopolies Act to End Conflicts of Interest Between Pharmacies, PBMs
Drug Topics
DECEMBER 13, 2024
US Senators introduced the bipartisan bill addressing pharmacy benefit managers and their affiliated pharmacies.
STAT+: Eli Lilly to test obesity medications as treatments for alcohol and drug addiction, CEO says
STAT
DECEMBER 10, 2024
Eli Lilly, the company that makes the blockbuster weight loss treatment Zepbound, will start studying its obesity products as treatments for alcohol and drug abuse, making it the first major drugmaker to do so, CEO David Ricks said Tuesday. Emerging research suggests that GLP-1 drugs — Zepbound is one such treatment — not only reduce food cravings but may also suppress desires for other substances.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Does drinking water lower blood pressure?
The Checkup by Singlecare
DECEMBER 9, 2024
Hypertension, or high blood pressure , affects nearly half of American adults. According to the Centers for Disease Control and Prevention (CDC) , only one in four have the condition under controland thats a problem. Why? Hypertension increases your risk of heart disease and stroke, the leading causes of death in the United States. Many factors influence blood pressure, from dietary choices and physical activity levels to how well you manage stress.
Pharmacists Play Key Role in Educating Patients About RSV Vaccine | ASHP Midyear
Drug Topics
DECEMBER 12, 2024
A conversation with Chelsea Keedy, PharmD, BCACP, clinical assistant professor at the University of Georgia.
STAT+: Pfizer’s abrupt withdrawal of sickle cell drug Oxbryta called ‘tone deaf’ at ASH conference
STAT
DECEMBER 8, 2024
SAN DIEGO — Pfizer’s abrupt withdrawal of its sickle cell drug Oxybryta over safety concerns was called “tone deaf” during a panel discussion among sickle cell experts Saturday at STAT@ASH , which took place during the American Society of Hematology’s annual meeting. They said patients were despondent over how suddenly the drug was pulled from the market in September because there had been no clear indication of problems in advance of the announcement.
GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration?
PharmaVoice
DECEMBER 11, 2024
The agency has yet to make a decision about keeping tirzepatide on or off of its shortage list — letting compound pharmacies continue their lucrative operations for now.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
How does weight loss drug Mounjaro work and why is it in such high demand?
The Guardian - Pharmaceutical Industry
DECEMBER 7, 2024
The King Kong of weight loss drugs will be available on the NHS but only patients with most need will get it Mounjaro, known as the King Kong of weight loss drugs, will be available to patients on the NHS, but this week it was announced the medication will be prioritised to people with the highest needs with the rollout expected to extend over 12 years.
Top Products to Help with Winter Skin Concerns | ASHP Midyear
Drug Topics
DECEMBER 11, 2024
Ethan Melillo, PharmD, CDOE, senior manager of Integrated Health at LOral, provides some of his favorite recommendations to help with irritated skin.
STAT+: Wall Street wags say a bill to force insurers or PBMs to sell pharmacies has low odds
STAT
DECEMBER 11, 2024
A proposed Senate bill that would prohibit companies that control health insurers or pharmacy benefit managers from owning pharmacies rattled investors on Wednesday, but some Wall Street analysts believe the legislation is unlikely to gain much traction, at least for now. The bipartisan bill , which would require divestiture within three years, is aimed at what the lawmakers call an “inherent conflict of interest” that has forced Americans to pay more for medicines and hastened the
ASHP Midyear: Nearly Half of Adults With Epilepsy Use CBD Products
Pharmacy Times
DECEMBER 9, 2024
Adults with epilepsy are underrepresented in most CBD trials, including common etiologies.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Is compounded semaglutide safe?
The Checkup by Singlecare
DECEMBER 12, 2024
Semaglutide has become a very popular drug thats in high demand in pharmacies everywhere and is currently also available from compounding pharmacies and online. But not all compounded semaglutide products are safe. In fact, the Food and Drug Administration (FDA) says consumers should exercise a lot of caution when considering using a compounded drug.
Navigating Cannabis Use in Health Care Settings | ASHP Midyear
Drug Topics
DECEMBER 8, 2024
Navigating Cannabis use requires more than just an understanding of the endocannabinoid system.
STAT+: BIOSECURE Act, aimed at Chinese drug manufacturers, is dealt a major blow
STAT
DECEMBER 8, 2024
WASHINGTON — Legislation to restrict U.S. drugmakers from using key Chinese contract manufacturers was dealt a major blow when senators left it out of a must-pass defense budget bill this weekend. The BIOSECURE Act would prohibit pharmaceutical and biotechnology companies from using services or equipment from Chinese “companies of concern,” including WuXi AppTec and WuXi Biologics, in work that is contracted or funded by the U.S. federal government.
ASHP: Identify and Counsel Patients at High Risk for Severe COVID-19
Pharmacy Times
DECEMBER 8, 2024
By identifying patients at high risk for progressing to severe disease and counseling them on their treatment options, pharmacists empower patients to make informed decisions about their treatment.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Reprieve for Chinese biotechs as BIOSECURE Act left out of key bill
Pharmaceutical Technology
DECEMBER 9, 2024
Shares in WuXi AppTec, one of those implicated in the Chinese biotech blacklisting legislation, surged following the omission.
Q&A: Pharmacist Discusses Unique Challenges in Psychiatric Population
Drug Topics
DECEMBER 12, 2024
Nina Vadiei, PharmD, BCPP, discusses some of the challenges she faces working with forensic patients who have been charged with a crime and have severe mental illness.
STAT+: Pharmalittle: We’re reading about a bill to force insurers to sell pharmacies, Lilly testing GLP-1 meds for addiction, and more
STAT
DECEMBER 11, 2024
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.
Fixed-Duration Acalabrutinib and Venetoclax Regimens Redefine First-Line Treatment Options for Patients With CLL
Pharmacy Times
DECEMBER 8, 2024
The phase 3 AMPLIFY trial demonstrates that fixed-duration regimens of acalabrutinib and venetoclax, with or without obinutuzumab, significantly improve progression-free survival and deliver manageable safety profiles compared to chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia (CLL).
After Moderna's pediatric RSV vaccine trial hold, expert panel says more testing is needed
Fierce Pharma
DECEMBER 13, 2024
Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that involve young children, experts from an FDA advisory panel expressed their | An FDA advisory committeeexamining the halt of a trial of two Moderna respiratory syncytial virus (RSV) vaccines because of severe lower respiratory tract infections (LRTIs)echoed frustration in knowledge gaps about the disease and said that more testing is needed.
In This Issue: Total Pharmacy December 2024
Drug Topics
DECEMBER 13, 2024
See whats trending in pharmacy with a preview of the Total Pharmacy December issue.
STAT+: Young biotech venture firm raises $500 million for its second fund
STAT
DECEMBER 9, 2024
What happens when two computer scientists and a former stem cell researcher become friends while working their way up the venture capital corporate ladder and decide to start their own firm? Well, in Dimension’s case, they end up investing in some buzzy AI startups, counseling pharmaceutical companies, ribbing one another about expense reports, and — as of Monday — are able to raise $500 million for their second fund.
FDA Grants Fast Track Designations to 2 Combination Influenza and COVID-19 Vaccine Candidates
Pharmacy Times
DECEMBER 11, 2024
The combination vaccine candidates will be evaluated in 2 separate phase 1/2 clinical trials.
Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company
Pharmafile
DECEMBER 12, 2024
12 December 2024 London, UK, and Palo Alto, CA, US Deep Science Ventures, a UK-based venture studio, and General Inception, a US-based venture studio, today announced a collaboration to create a company focused on developing novel treatments for fibrosis. Widely recognised as an area of significant unmet need, Deep Science Ventures and General […] The post Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company appeared first on Pharmafile.
Psychiatric Pharmacist Working to Optimize Treatment, Improve Patient Safety
Drug Topics
DECEMBER 13, 2024
A conversation with Nina Vadiei, PharmD, BCPP, clinical associate professor in the Division of Pharmacotherapy at University of Texas at Austin College of Pharmacy and a clinical pharmacy specialist in psychiatry at the San Antonio State Hospital.
STAT+: Pharmalittle: We’re reading about unsupported drug price hikes, an annual HIV prevention shot, and more
STAT
DECEMBER 12, 2024
Top of the morning to you, and a fine one it is. Clear blue skies and chilly breezes are wafting across the Pharmalot campus, where the official mascots are snoozing after foraging for their breakfast. This means we are free to focus on the matters at hand — rummaging through our to-do list and making cups of stimulation. Our choice today is maple cinnamon French toast.
ASHP Midyear: High Costs of Gene Therapies Present Major Challenges to Implementation
Pharmacy Times
DECEMBER 11, 2024
According to the report, 75% of survey participants expect pharmacists to oversee these therapies and 58% expect Medicare will require pharmacist involvement.
Nobel laureates ‘strongly urge’ Senate to oppose confirmation of RFK Jr
Pharmaceutical Technology
DECEMBER 12, 2024
In the letter, 77 Nobel Prize winners argue that appointing RFK as Secretary of HHS would put the US publics health in jeopardy.
Q&A: Pharmacists’ Understanding of CKD Therapies, Adverse Effects | ASHP Midyear
Drug Topics
DECEMBER 13, 2024
Denise Kelley, PharmD, BCPS, FASHP, joined Drug Topics to discuss various medications for chronic kidney disease and their common adverse reactions.
STAT+: Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815M in 2023, report finds
STAT
DECEMBER 12, 2024
During 2023, drugmakers substantially raised prices on five widely used medicines without any new clinical evidence to justify the increases, leading patients and health insurers in the U.S. to spend an additional $815 million last year, according to a new report. The drug for which spending increased the most due to a price increase was Biktarvy, which is prescribed to treat HIV and is a franchise product for Gilead Sciences.
Let's personalize your content